Edgar Filing: SHANAHAN WILLIAM R JR - Form 4

SHANAHAN Form 4 March 05, 20	V WILLIAM R J 08	R									
FORM 4 UNITED STATES SECURITIES AND EXCHANCE COMMISSION								-	PPROVAL		
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction UNITED STATES SECURITIES AND EXCHANGE COMMISSIO Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 193 Section 17(a) of the Public Utility Holding Company Act of 1935 or Sec 30(h) of the Investment Company Act of 1940							COMMISSION	OMB Number:	3235-0287		
							xchan Act o	ge Act of 1934, of 1935 or Sectio	Estimated average burden hours per response 0.5		
1(b). (Print or Type R	esponses)										
J1											
			2. Issuer Name and Ticker or Trading Symbol ARENA PHARMACEUTICALS INC [ARNA]					5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last) C/O ARENA PHARMACI NANCY RII	A EUTICALS, IN	Middle) C., 6166		of Earliest Tr Day/Year) 2008	ransaction			Director X Officer (giv below) VP, Ch		% Owner her (specify ficer	
Filed(M				endment, Da onth/Day/Yea	-	ıl		6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting			
SAN DIEGO), CA 92121							Person		eporting	
(City)	(State)	(Zip)	Tab	le I - Non-I	Derivative	Securi	ties Ac	cquired, Disposed o	of, or Beneficia	lly Owned	
	2. Transaction Date Month/Day/Year)	2A. Deemo Execution any (Month/Da	Date, if	3. Transactio Code (Instr. 8) Code V	Disposed (Instr. 3, 4	(A) or of (D))	Securities Beneficially Owned	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Reminder: Repo	ort on a separate line	for each of	ass of see					rindirectly			
Rennuer. Rept	sit on a separate find			unities bellel	including Ow	neu une	cetty Of	maneeuy.			

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. 5. Number of TransactiorDerivative Code Securities (Instr. 8) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)			
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	\$ 6.99	03/03/2008		A		45,000		<u>(1)</u>	03/03/2018	Common Stock	45,000

Edgar Filing: SHANAHAN WILLIAM R JR - Form 4

Reporting Owners

Reporting Owner Name / Address	Relationships							
	Director	10% Owner	Officer	Other				
SHANAHAN WILLIAM R JR C/O ARENA PHARMACEUTICALS, INC. 6166 NANCY RIDGE DRIVE SAN DIEGO, CA 92121			VP, Chief Medical Officer					
Signatures								
Adam S. Chinnock, as Attorney-in-Fact)3/05/2008	}						

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The options vest in four equal annual installments (except as otherwise necessary to avoid vesting of a fractional share), beginning on March 3, 2009, and are exercisable once vested.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.